SCHEMBL958236

SCHEMBL958236

COCOc1ccc(C(C)(C)C)cc1C(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.48
MAPK1 P28482 4/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 5/20 0.41
NPSR1 Q6W5P4 3/20 0.40
CYP2C19 P33261 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
MAPT P10636 1/20 0.40
TRPV1 Q8NER1 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
RECQL P46063 1/20 0.36
APEX1 P27695 1/20 0.36
ALDH1A1 P00352 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RXRA P19793 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29607317 1.00 EGFR (0.48) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL27170735 0.91 KDM4E (0.45) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL1535626 0.84 LMNA (0.51) MAPK1LMNAHTTKDM4ENPSR1
SCHEMBL6902107 0.83 ALDH1A1 (0.40) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL1042008 0.82 USP2 (0.44) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL30087029 0.82 USP2 (0.44) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL6671333 0.81 ALDH1A1 (0.47) MAPK1HTTKDM4ENPSR1CYP2C19
SCHEMBL23120088 0.81 RBP4 (0.45) MAPK1LMNAHTTPTGDR2SMN1; SMN2
SCHEMBL12772150 0.81 ALDH1A1 (0.50) EGFRMAPK1LMNAHTTKDM4E
SCHEMBL29607406 0.81 RBP4 (0.45) MAPK1LMNAHTTPTGDR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12291593-B2 Compounds for use in catalyst compositions for the production of polyolefins SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2025-05-06 US disclosed
EP-4031592-B1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS SABIC GLOBAL TECHNOLOGIES BV (NL) 2025-04-30 EP disclosed
CN-114423769-B Compounds in catalyst compositions for the production of polyolefins SABIC环球技术有限责任公司 2024-04-26 CN disclosed
US-20220356275-A1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2022-11-10 US disclosed
CN-114423769-A Compounds for use in catalyst compositions for the production of polyolefins SABIC环球技术有限责任公司 2022-04-29 CN disclosed
EP-2456795-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS Equistar Chemicals, LP (US) 2012-05-30 EP disclosed
EP-2456793-A1 CATALYSTS BASED ON 2-(2-ARYLOXY) QUINOLINE OR 2-(2-ARYLOXY) DIHYDROQUNIOLINE LIGANDS Equistar Chemicals, LP (US) 2012-05-30 EP disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
US-8158733-B2 Catalysts based on 2-(2-aryloxy)quinoline or 2-(2-aryloxy)dihydroquinoline ligands EQUISTAR CHEMICALS, LP (US) 2012-04-17 US disclosed
WO-2011011039-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS EQUISTAR CHEMICALS, LP (US) 2011-01-27 WO disclosed
WO-2011011039-A1 METHOD OF PREPARING NON-METALLOCENE CATALYSTS EQUISTAR CHEMICALS, LP (US) 2011-01-27 WO disclosed
US-20110021344-A1 Method for preparing non-metallocene ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
US-20110021344-A1 Method for preparing non-metallocene ligands EQUISTAR CHEMICALS, LP 2011-01-27 US disclosed
EP-2272852-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex Sumitomo Chemical Company, Limited (JP) 2011-01-12 EP disclosed
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED 2009-06-04 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-7482414-B2 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-27 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220356275-A1 COMPOUNDS FOR USE IN CATALYST COMPOSITIONS FOR THE PRODUCTION OF POLYOLEFINS RPLP0, RPS20, RPS10 EGFR 601/4885MAPK1 2744/4885LMNA 1510/4885
US-20070135600-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 EGFR 895/4885MAPK1 1478/4885LMNA 3039/4885
US-20090143620-A1 Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex AP1M1, OR10J3, AP2M1 EGFR 895/4885MAPK1 1478/4885LMNA 3039/4885
US-12291593-B2 Compounds for use in catalyst compositions for the production of polyolefins RPLP0, RPS20, RPS10 EGFR 601/4885MAPK1 2744/4885LMNA 1510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.